» Articles » PMID: 32765262

Clinical and Preclinical Systematic Review of C. A. Mey and Its Compounds for Fatigue

Overview
Journal Front Pharmacol
Date 2020 Aug 9
PMID 32765262
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fatigue, as a complex, multidimensional symptom, is associated with many physical illnesses. C. A. Mey (PG) is an important herbal drug which has been used for benefiting Qi for thousand years. C. A. Mey and its compounds (PGC) possess various pharmacological activities, including anti-fatigue. Here, we conducted a systematic review of both randomized clinical trials (RCTs) and preclinical animal studies to investigate the efficacy and safety of PGC for fatigue.

Methods: Electronic searches were performed in 7 databases from the time of each database's inception to August 2019. The methodological quality of RCTs was assessed using 7-item checklist recommended by Cochrane Collaboration or by the CAMARADES 10-item quality checklist. All the data were analyzed using Rev-Man 5.3 and Stata SE software.

Results: Eight eligible RCTs and 30 animal studies were identified. The risk of bias scores in RCTs ranged from 4/7 to 7/7, and of animal studies varied from 4/10 to 7/10. Meta-analyses showed that PGC was superior to placebo according to their respective fatigue scales, heart rate recovery, and clinical effect (P < 0.05). There were a similar number of adverse effects between PGC and placebo group (P > 0.05). Meta-analyses showed that PGC can significantly decrease level of blood lactate, blood urea nitrogen, creatine kinase, malondialdehyde, and lactic dehydrogenase in serum, level of malondialdehyde in liver and level of gamma-aminobutyric acid, 5-hydroxytryptamine in brain tissue, and increase swimming time, level of glutathione peroxidase, glucose, superoxide dismutase in serum, level of glycogen and activity of superoxide dismutase, glutathione peroxidase, and catalase in skeletal muscle, level of hepatic glycogen in liver and level of dopamine, acetylcholine in brain tissue, compared with control (P < 0.05). Meta-analyses showed no significant difference in animal body weight between PGC and control (P > 0.05).

Conclusion: The present findings supported, to a certain degree, that PGC can be recommended for routine use in fatigue. The possible mechanism of PGC resists fatigue, mainly through antioxidant stress, regulating carbohydrate metabolism, delaying the accumulation of metabolites, promoting mitochondrial function, neuroprotection, antiapoptosis, and regulating neurotransmitter disorder in central nervous system.

Citing Articles

Screening tools to evaluate the neurotoxic potential of botanicals: building a strategy to assess safety.

Kanungo J, Sorkin B, Krzykwa J, Mitchell C, Embry M, Spencer P Expert Opin Drug Metab Toxicol. 2024; 20(7):629-646.

PMID: 38984683 PMC: 11542175. DOI: 10.1080/17425255.2024.2378895.


Antifatigue Effects of the Aqueous Extracts of Myrtle Berries, Apple and Clove: An Animal Study.

Alembagheri A, Hajimehdipoor H, Khoramjouy M, Esmaeili S, Faizi M Iran J Pharm Res. 2024; 22(1):e140323.

PMID: 38444713 PMC: 10912872. DOI: 10.5812/ijpr-140323.


Complementary medicine for fatigue: the importance of basic sciences and clinical studies.

Asian Biomed (Res Rev News). 2023; 17(4):150-151.

PMID: 37860675 PMC: 10584380. DOI: 10.2478/abm-2023-0055.


Efficacy and safety of methylphenidate and ginseng in cancer-related fatigue: a network meta-analysis of randomized controlled trials.

Li H, Che K, Zhi Z, Xu W, Huang J, Wang X Transl Cancer Res. 2023; 12(4):732-742.

PMID: 37180654 PMC: 10174756. DOI: 10.21037/tcr-22-2303.


Protective effects of Korean Red Ginseng against toxicity of endocrine-disrupting chemicals.

Jung E, Lee S, Lee G J Ginseng Res. 2023; 47(2):193-198.

PMID: 36926605 PMC: 10014227. DOI: 10.1016/j.jgr.2022.11.007.


References
1.
Kim H, Cho J, Yoo S, Lee J, Han J, Lee N . Antifatigue effects of Panax ginseng C.A. Meyer: a randomised, double-blind, placebo-controlled trial. PLoS One. 2013; 8(4):e61271. PMC: 3629193. DOI: 10.1371/journal.pone.0061271. View

2.
Krupp L, Larocca N, Steinberg A . The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989; 46(10):1121-3. DOI: 10.1001/archneur.1989.00520460115022. View

3.
Oh H, Kim D, Choi H, Kim N, Kim D . Anti-fatigue Effects of 20(S)-Protopanaxadiol and 20(S)-Protopanaxatriol in Mice. Biol Pharm Bull. 2015; 38(9):1415-9. DOI: 10.1248/bpb.b15-00230. View

4.
Kilkenny C, Browne W, Cuthi I, Emerson M, Altman D . Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Vet Clin Pathol. 2012; 41(1):27-31. DOI: 10.1111/j.1939-165X.2012.00418.x. View

5.
Yennurajalingam S, Tannir N, Williams J, Lu Z, Hess K, Frisbee-Hume S . A Double-Blind, Randomized, Placebo-Controlled Trial of for Cancer-Related Fatigue in Patients With Advanced Cancer. J Natl Compr Canc Netw. 2017; 15(9):1111-1120. DOI: 10.6004/jnccn.2017.0149. View